Bruno STANKOFFMD, PhD, PU-PH, Sorbonne University, AP-HP
RepairMain domain: Cellular & molecular neuroscienceSubdomain : Clinical & translational neuroscienceCatherine LUBETZKI & Bruno STANKOFFs team aims to tackle the mechanisms of CNS myelin repair through complementary approaches and expertise in Multiple sclerosis and demyelinating disorders.For more information
NEUROGENCELL Main field : Clinical & translational neurosciences Secondary domain: Molecular & cellular neurosciences The "NEUROGENCELL" team develops gene and cell therapy strategies for severe neurodegenerative diseases of adults and children: Amyotrophic lateral sclerosis, Huntington's, Spinocerebellar ataxias, Parkinson's and Rett syndrome. As well as paediatric overload diseases: genetic leukodystrophies and mucopolysaccharidoses. This research includes proof of concepts in animal models and translational steps towards clinical applications.
The "NEUROGENCELL" team is also developing tools for the entry of therapeutic molecules into the brain (vectors that can be administered by the venous route, optogenetics, use of microglia as a therapeutic vector, use of ultrasound to improve the passage of vectors across the blood-brain barrier). For more information
Richard LEVYMD, PhD, PU-PH, Sorbonne university, AP-HP
Connectivity: frontal parietal,temporal and frontal-subcortical networksMain domain: CognitionSubdomain : Clinical & translational neurosciencesThe activities of the FRONTLAB team is a true collective research structured in 4 main tracks, all focused on the anatomical and functional organisation of the frontal lobes and associated networks for higher-order cognition in health and disease.
The first track (human cognition) studies on how the human brain generates and valuates creative ideas. Computational modeling combined with cognitive tasks, neuroimaging, intraoperative recordings of brain activity in awake surgery and noninvasive brain stimulation are applied to investigate interaction between the processes of generating new ideas and those required to evaluate their appropriateness and originality.
The second track (human behaviour), addresses how goal-directed behaviour is generated and what are the pathophysiological mechanisms underlying abnormally expressed goal directed behaviours, in particular, disinhibition and apathy). Our approach relies on classical approaches combined with the analysis of human behaviour in close to real-life situations using simulated scenarios in the lab or wired tracking devices at home.
The third track (human brain organisation), investigates at the network level the causal structural and neurophysiological basis of cognitive functions and their impairments in healthy individuals and neurosurgical patients. It also addresses the characterization of activity states subtending the allocation, control and transient loss of sustained attention and its modulation with invasive and non-invasive brain stimulation technologies.
The fourth track (“bench to bedside”) is a translational clinical program aiming to characterize genetic, molecular, neurophysiological and anatomical impairments leading to neuropsychiatric symptoms impacting frontal networks or explaining disease vulnerability. Multimodal approaches are applied to phenotype large cohorts of FTLD patients and on such basis contain their progression or reverse its symptoms with or molecular approaches or non-invasive brain stimulation (rTMS, tDCS, tACS).
New website : https://sites.google.com/view/frontlab-icm/For more information
Main domain: CognitionSubdomain : Clinical & translational neuroscienceLaurent Cohen, Lionel Naccache & Paolo Bartolomeo’s team explores the neural bases of cognitive functions in humans.
They work with both healthy and brain-damaged persons, using behavioral methods and a full panel of brain imaging techniques (anatomical, functional and diffusion-based MRI, EEG, MEG, intracerebral recordings). For more information
Methodology and neuroimagingMain domain: Clinical & translational neurosciencesOlivier COLLIOT & Stanley DURRLEMAN’s team, the ARAMIS team aims to build numerical models of brain diseases from multimodal patient data based on the development of specific data-driven approaches.
The main research axes are
Integrate multimodal neuroimaging data (PET, microstructure, ASL) to fully characterize alterations
Model the temporal dynamics of disease
Model brain networks
Integrate imaging with other types of data (in particular omics and clinical data)
Vincent NAVARROMD, PhD, PU-PH, Sorbonne university, AP-HP
Dynamics and physiopathology of neural networks, epilepsyMain domain: NeurophysiologySubdomain : Clinical & translational neurosciencesOur team investigates the pathophysiological processes making the brain epileptic (epileptogenesis) and how the mechanisms responsible for the occurrence of seizures (ictogenesis). These two dimensions of epileptic diseases are explored using a translational and multiscale strategy: from validated animal models to clinical semiology and from single neurons to large scale networks. Specifically, the research includes in vivo EEG and cell recordings from both human epileptic patients and animal models exhibiting spontaneous (genetic models) or provoked (drugs or stimulation-induced) seizures. For more information
Alexandra DURRMD, PhD, PU-PH, Sorbonne university-AP-HP
Giovanni STEVANINPhD, DR2, PU, INSERM/EPHE
Physiopathology of neurological disordersMain domain : Cellular & molecular neurosciencesSubdomain : Clinical & translational neurosciencesAlexandra DURR & Giovanni STEVANIN’s team focus on two groups of neurogenetic diseases, spinocerebellar degenerations – SCD (spastic paraplegias and cerebellar ataxias) and frontotemporal lobar degenerations – FTLD. These rare conditions share clinical, genetic and functional characteristics, such as motor neuron dysfunction but are extremely heterogeneous both in molecular and clinical aspects. For more information
Main domain : Cellular & molecular neurosciencesSubdomain : Clinical & translational neurosciencesSéverine BOILLEE’s team investigates mechanisms of motor neuron (MN) degeneration in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) resulting from pathological interactions between MNs and microglia/macrophages to find therapeutically promising pathways to slow disease progression through two main aims:For more information
Adaptive Behavior, Cortico - Basal Ganglia circuits, DBS/OptogeneticMain domain: NeurophysiologySubdomain : CognitionEric BURGUIERE’s team aims to implement an ambitious translational approach to characterize neurofunctional basis of normal and pathological repetitive behaviors. The main focus of the team is to study neurophysiological dynamics underlying the automatization of motivated behaviours and its contextual adaptation. The team has access to both patients and animal models suffering from pathological repetitive behaviors. For more information